Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenly Sikwese

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
PLOS Global Public Health|March 11, 2024
Community-friendly diagnostics: Who are tests for?Fifa A Rahman, Kenly Sikwese
AIDS and Behavior|July 11, 2024
Ensuring People Living with HIV Inform the Future of HIV Treatment in Low- and Middle-Income Countries: A Scoping Review and Recommendations for a Community-Led Research AgendaDanielle F Resar, Rachel Sapire, Benvy Caldwell, et al.
Health and Human Rights|July 24, 2015
Evolving Human Rights and the Science of Antiretroviral MedicineMatthew Kavanagh, Jennifer Cohn, Lynette Mabote, et al.
AIDS (London, England)|December 1, 2021
What we have learned from antiretroviral treatment optimization efforts over the last 5 years?W D Francois Venter, Celicia Serenata, Marco Vitoria, et al.
The Lancet. Global Health|June 29, 2026
Sustaining progress in HIV care in Africa with a transition to enabled self-care: a modelling studyAndrew N Phillips, Kenly Sikwese, Valentina Cambiano, et al.
Nature Communications|July 2, 2025
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
AIDS (London, England)|July 25, 2022
Enabling timely HIV postexposure prophylaxis access in sub-Saharan AfricaAndrew N Phillips, Euphemia Sibanda, Kenly Sikwese, et al.
Nature Communications|April 17, 2026
Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
The Lancet. Global Health|September 21, 2023
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysisAndrew N Phillips, Loveleen Bansi-Matharu, Maryam Shahmanesh, et al.
Journal of the International AIDS Society|July 13, 2019
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defectsLynne M Mofenson, Anton L Pozniak, Jacque Wambui, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
PLOS Global Public Health|March 11, 2024
Community-friendly diagnostics: Who are tests for?Fifa A Rahman, Kenly Sikwese
AIDS and Behavior|July 11, 2024
Ensuring People Living with HIV Inform the Future of HIV Treatment in Low- and Middle-Income Countries: A Scoping Review and Recommendations for a Community-Led Research AgendaDanielle F Resar, Rachel Sapire, Benvy Caldwell, et al.
Health and Human Rights|July 24, 2015
Evolving Human Rights and the Science of Antiretroviral MedicineMatthew Kavanagh, Jennifer Cohn, Lynette Mabote, et al.
AIDS (London, England)|December 1, 2021
What we have learned from antiretroviral treatment optimization efforts over the last 5 years?W D Francois Venter, Celicia Serenata, Marco Vitoria, et al.
The Lancet. Global Health|June 29, 2026
Sustaining progress in HIV care in Africa with a transition to enabled self-care: a modelling studyAndrew N Phillips, Kenly Sikwese, Valentina Cambiano, et al.
Nature Communications|July 2, 2025
Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
AIDS (London, England)|July 25, 2022
Enabling timely HIV postexposure prophylaxis access in sub-Saharan AfricaAndrew N Phillips, Euphemia Sibanda, Kenly Sikwese, et al.
Nature Communications|April 17, 2026
Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in AfricaAndrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, et al.
The Lancet. Global Health|September 21, 2023
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysisAndrew N Phillips, Loveleen Bansi-Matharu, Maryam Shahmanesh, et al.
Journal of the International AIDS Society|July 13, 2019
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defectsLynne M Mofenson, Anton L Pozniak, Jacque Wambui, et al.
Pageof 2